ABCAM Plc Notice of Interim Results (6577E)
February 11 2015 - 8:20AM
UK Regulatory
TIDMABC
RNS Number : 6577E
ABCAM Plc
11 February 2015
For immediate release 11 February
2015
ABCAM PLC
("Abcam" or "the Company")
Notification of Interim Results
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, will announce its interim
results for the six months ended 31 December 2014 on Monday 9 March
2015.
A briefing for analysts will be held at 0930 (UK time) on 9
March at the offices of Brunswick Group LLP, 16 Lincoln's Inn
Fields, London, WC2A 3ED.
A live audio webcast and slide presentation of this event will
be available at www.abcamplc.com, for which we recommend you
register by 0915 (UK time). There will also be a conference call
dial-in available - details will be provided in the announcement of
interim results at 0700 on 9 March.
For further information please contact:
+ 44 (0) 1223
Abcam 696 000
Jeff Iliffe, Chief Financial Officer
Laura Taylor, Investor Relations Manager
J.P.Morgan Cazenove - Nominated Adviser & Joint + 44 (0) 20 7742
Corporate Broker 4000
James Mitford / Alex Bruce - Nominated Adviser
+ 44 (0) 20 7418
Peel Hunt LLP - Joint Corporate Broker 8900
Clare Terlouw / Jock Maxwell MacDonald - Corporate
Broking
+44 (0) 20 7404
Brunswick 5959
Justine Mcllroy / Will Medvei / Anna Carruth
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science
research tools, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level and improving the understanding of health and
disease.
Abcam is committed to providing scientists with an extensive
choice of reagents and tools, with the most comprehensive, honest
and up-to-date datasheets and customer reviews, fast delivery and
helpful customer service & technical support. The Company's
catalogue evolves with scientific research trends and is growing
each year to provide customers with products to meet their research
needs. The range now includes primary and secondary antibodies,
proteins, peptides, lysates, biochemicals, immunoassays and other
kits. Abcam also supports its customers by hosting a range of
global scientific events, forums and webinars, providing
opportunities for scientists to get together and present their
work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices enabling local services and multi-language support and
sells to over 100 countries. The Company was founded in 1998, and
now employs over 750 people. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFLSFAILLIE
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024